Search research articles
Contact Us
Filters
Showing results (141-150 of 149) with videos related to
Page
of 15
Sort By:
You have reached the last page of results.
This site can display upto 149 results.
Haematologica
|
February 2, 2015
Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study)
Morena Caira, Anna Candoni, Luisa Verga, et al.
Hematological Oncology
|
February 3, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study
Enrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Haematologica
|
July 13, 2023
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials
Massimo Gentile, Ernesto Vigna, Salvatore Palmieri, et al.
Frontiers in Oncology
|
August 4, 2022
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
Fortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Hematological Oncology
|
May 31, 2024
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials
Enrica Antonia Martino, Salvatore Palmieri, Monica Galli, et al.
Hematological Oncology
|
May 24, 2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
Antonella Bruzzese, Daniele Derudas, Monica Galli, et al.
Haematologica
|
March 6, 2025
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
Enrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.
European Journal of Haematology
|
March 19, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients
Fortunato Morabito, Enrica Antonia Martino, Monica Galli, et al.
The Lancet. Haematology
|
May 4, 2020
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Michele Cavo, Francesca Gay, Meral Beksac, et al.
Page
of 15
Search research articles
Search
Showing results (141-150 of 149) with videos related to
Sort By:
Page
of 15
You have reached the last page of results.
This site can display upto 149 results.
Haematologica
|
February 2, 2015
Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study)
Morena Caira, Anna Candoni, Luisa Verga, et al.
Hematological Oncology
|
February 3, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study
Enrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Haematologica
|
July 13, 2023
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials
Massimo Gentile, Ernesto Vigna, Salvatore Palmieri, et al.
Frontiers in Oncology
|
August 4, 2022
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
Fortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Hematological Oncology
|
May 31, 2024
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials
Enrica Antonia Martino, Salvatore Palmieri, Monica Galli, et al.
Hematological Oncology
|
May 24, 2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
Antonella Bruzzese, Daniele Derudas, Monica Galli, et al.
Haematologica
|
March 6, 2025
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
Enrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.
European Journal of Haematology
|
March 19, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients
Fortunato Morabito, Enrica Antonia Martino, Monica Galli, et al.
The Lancet. Haematology
|
May 4, 2020
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Michele Cavo, Francesca Gay, Meral Beksac, et al.
Page
of 15